Applying the use of novel biomarkers for neuroendocrine tumors in the clinic : where are we now?
应用新型生物标志物在临床神经内分泌肿瘤中的应用:我们现在在哪里?
{"title":"Applying the use of novel biomarkers for neuroendocrine tumors in the clinic: where are we now?","authors":"K. Daskalakis, O. Norlén, P. Hellman, P. Stålberg","doi":"10.2217/IJE-2017-0012","DOIUrl":"https://doi.org/10.2217/IJE-2017-0012","url":null,"abstract":"Applying the use of novel biomarkers for neuroendocrine tumors in the clinic : where are we now?","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJE-2017-0012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43326643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Welcome to Volume 6 of International Journal of Endocrine Oncology","authors":"Jennifer Straiton","doi":"10.2217/IJE-2018-0005","DOIUrl":"https://doi.org/10.2217/IJE-2018-0005","url":null,"abstract":"","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJE-2018-0005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46205660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
C. Passaro, S. D. Somma, A. Malfitano, G. Portella
Oncolytic viruses (OVs) selectively infect and lyse cancer cells. A direct lytic effect of OVs has been theorized in the initial studies; however, the antineoplastic effect of OVs is also due to the induction of an immune response against cancer cells. Anaplastic thyroid cancer is one of the most aggressive human malignancies with a short survival time of about 6–12 months from the diagnosis. The lack of effective therapies has prompted to investigate the efficacy of OVs in anaplastic thyroid carcinoma. Different OVs have been tested in preclinical studies, either as single agents or in combinatorial treatments. In this review, the results of these studies are summarized and future perspective discussed.
{"title":"Oncolytic virotherapy for anaplastic and poorly differentiated thyroid cancer: a promise or a clinical reality?","authors":"C. Passaro, S. D. Somma, A. Malfitano, G. Portella","doi":"10.2217/IJE-2017-0028","DOIUrl":"https://doi.org/10.2217/IJE-2017-0028","url":null,"abstract":"Oncolytic viruses (OVs) selectively infect and lyse cancer cells. A direct lytic effect of OVs has been theorized in the initial studies; however, the antineoplastic effect of OVs is also due to the induction of an immune response against cancer cells. Anaplastic thyroid cancer is one of the most aggressive human malignancies with a short survival time of about 6–12 months from the diagnosis. The lack of effective therapies has prompted to investigate the efficacy of OVs in anaplastic thyroid carcinoma. Different OVs have been tested in preclinical studies, either as single agents or in combinatorial treatments. In this review, the results of these studies are summarized and future perspective discussed.","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJE-2017-0028","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46798615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. Sastry, E. Williams, Robert M. Koffie, K. Fehnel, L. Wirth, B. Nahed
Medullary thyroid cancer rarely metastasizes to the brain. Presentation and optimal treatment approaches vary widely. We present a 53-year-old male, diagnosed with medullary thyroid cancer 21 years prior, who was presented with at least seven metastases in his brain. He underwent two craniotomies for two large, hemorrhagic metastases followed by whole brain radiation therapy. Tumor genotyping revealed a somatic C634R mutation in the RET proto-oncogene. Subsequently, he was started on multikinase inhibitor therapy. He ultimately passed away 10 months after his surgery. Complete resection may be a reasonable approach for patients with one or more cerebral or cerebellar metastases when feasible. Further analysis is necessary to understand the specific mutations that predispose medullary thyroid cancer to central nervous system metastasis.
{"title":"Metastatic medullary thyroid cancer to the brain: a case report and review of the literature","authors":"R. Sastry, E. Williams, Robert M. Koffie, K. Fehnel, L. Wirth, B. Nahed","doi":"10.2217/IJE-2017-0024","DOIUrl":"https://doi.org/10.2217/IJE-2017-0024","url":null,"abstract":"Medullary thyroid cancer rarely metastasizes to the brain. Presentation and optimal treatment approaches vary widely. We present a 53-year-old male, diagnosed with medullary thyroid cancer 21 years prior, who was presented with at least seven metastases in his brain. He underwent two craniotomies for two large, hemorrhagic metastases followed by whole brain radiation therapy. Tumor genotyping revealed a somatic C634R mutation in the RET proto-oncogene. Subsequently, he was started on multikinase inhibitor therapy. He ultimately passed away 10 months after his surgery. Complete resection may be a reasonable approach for patients with one or more cerebral or cerebellar metastases when feasible. Further analysis is necessary to understand the specific mutations that predispose medullary thyroid cancer to central nervous system metastasis.","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2018-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJE-2017-0024","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43098175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
• FOXL2 mutation is diagnostic, and, if pathology is in doubt, it should be performed. • Surgical resection and staging is key to assess prognosis. • Platinum-based adjuvant chemotherapy such as with carboplatin plus paclitaxel is a reasonable step for women diagnosed with distant recurrences or poor prognostic initial features. However, evidence for improved outcome is lacking. • Hormone-based therapies, especially with aromatase inhibitors, have shown activity and future studies may lead to further insight on the relationship of inhibition of hormonal pathways and tumor progression.
{"title":"Ovarian adult-type granulosa cell tumor: focusing on endocrine-based therapies","authors":"Annie Yang, J. Curtin, F. Muggia","doi":"10.2217/IJE-2017-0021","DOIUrl":"https://doi.org/10.2217/IJE-2017-0021","url":null,"abstract":"• FOXL2 mutation is diagnostic, and, if pathology is in doubt, it should be performed. • Surgical resection and staging is key to assess prognosis. • Platinum-based adjuvant chemotherapy such as with carboplatin plus paclitaxel is a reasonable step for women diagnosed with distant recurrences or poor prognostic initial features. However, evidence for improved outcome is lacking. • Hormone-based therapies, especially with aromatase inhibitors, have shown activity and future studies may lead to further insight on the relationship of inhibition of hormonal pathways and tumor progression.","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2018-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJE-2017-0021","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44826987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-02-02eCollection Date: 2018-02-01DOI: 10.2217/ije-2017-0005
Jasmine Shell, Xavier M Keutgen, Corina Millo, Naris Nilubol, Dhaval Patel, Samira Sadowski, Myriem Boufraqech, Lily Yang, Roxanne Merkel, Christine Atallah, Peter Herscovitch, Electron Kebebew
Aim: The study's aim was to determine the utility of 68-Gallium DOTATATE positron emission tomography (PET)-CT scanning in patients with carcinoid-like symptoms and negative anatomical imaging.
Methods: Retrospective analysis of 22 of 196 patients with carcinoid-like symptoms and no evidence of primary neuroendocrine tumor (NET) based on anatomical imaging and endoscopy who underwent 68-Gallium DOTATATE PET-CT as part of a prospective clinical trial.
Results: Of the biochemically positive patients (n = 11), 18% (n = 2) had additional evidence of NETs based on 68-Gallium DOTATATE PET-CT. Of the patients identified by 68-Gallium DOTATATE PET-CT, 50% (n = 1) had a treatment change and 100% showed symptom improvement. Of the biochemically negative patients (n = 11), 68-Gallium DOTATATE PET-CT identified NETs in 64% (n = 7). Change in management occurred in 71% patients, and 57% of patients showed symptom improvement.
Conclusion: 68-Gallium DOTATATE PET-CT imaging is useful in detecting NETs in symptomatic patients with negative anatomical imaging and changes the treatments in these patients.
{"title":"68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor.","authors":"Jasmine Shell, Xavier M Keutgen, Corina Millo, Naris Nilubol, Dhaval Patel, Samira Sadowski, Myriem Boufraqech, Lily Yang, Roxanne Merkel, Christine Atallah, Peter Herscovitch, Electron Kebebew","doi":"10.2217/ije-2017-0005","DOIUrl":"https://doi.org/10.2217/ije-2017-0005","url":null,"abstract":"<p><strong>Aim: </strong>The study's aim was to determine the utility of 68-Gallium DOTATATE positron emission tomography (PET)-CT scanning in patients with carcinoid-like symptoms and negative anatomical imaging.</p><p><strong>Methods: </strong>Retrospective analysis of 22 of 196 patients with carcinoid-like symptoms and no evidence of primary neuroendocrine tumor (NET) based on anatomical imaging and endoscopy who underwent 68-Gallium DOTATATE PET-CT as part of a prospective clinical trial.</p><p><strong>Results: </strong>Of the biochemically positive patients (n = 11), 18% (n = 2) had additional evidence of NETs based on 68-Gallium DOTATATE PET-CT. Of the patients identified by 68-Gallium DOTATATE PET-CT, 50% (n = 1) had a treatment change and 100% showed symptom improvement. Of the biochemically negative patients (n = 11), 68-Gallium DOTATATE PET-CT identified NETs in 64% (n = 7). Change in management occurred in 71% patients, and 57% of patients showed symptom improvement.</p><p><strong>Conclusion: </strong>68-Gallium DOTATATE PET-CT imaging is useful in detecting NETs in symptomatic patients with negative anatomical imaging and changes the treatments in these patients.</p>","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2018-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ije-2017-0005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36401644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
“ Surgeons cannot apply a new approach without a perfect grasp of the laryngeal nerves [7] . This would be in contrast with commonly performed routine, conventional surgery.
“如果没有对喉部神经的完美把握，外科医生就无法应用新的手术方法。这将与常规的常规手术形成对比。
{"title":"Endoscopic thyroid surgery requires surgeons, patient candidacy & neural monitoring","authors":"Hui Sun, G. Dionigi","doi":"10.2217/IJE-2018-0001","DOIUrl":"https://doi.org/10.2217/IJE-2018-0001","url":null,"abstract":"“ Surgeons cannot apply a new approach without a perfect grasp of the laryngeal nerves [7] . This would be in contrast with commonly performed routine, conventional surgery.","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2018-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJE-2018-0001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42112308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Exploiting RET isoforms in managing medullary and papillary thyroid cancer","authors":"Eric Y. Lian, S. Moodley, L. Mulligan","doi":"10.2217/IJE-2017-0029","DOIUrl":"https://doi.org/10.2217/IJE-2017-0029","url":null,"abstract":"","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2018-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJE-2017-0029","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49463171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Current and future treatments for parathyroid carcinoma","authors":"Kristin L. Long, R. Sippel","doi":"10.2217/IJE-2017-0011","DOIUrl":"https://doi.org/10.2217/IJE-2017-0011","url":null,"abstract":"","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2018-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJE-2017-0011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48337118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：